# Pyrimethamine for Intermediate/High-risk Myelodysplastic Syndromes (MDS)

> **NCT03057990** · PHASE1 · WITHDRAWN · sponsor: **Montefiore Medical Center**

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Pyrimethamine

## Key facts

- **NCT ID:** NCT03057990
- **Lead sponsor:** Montefiore Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-09-11
- **Primary completion:** 2021-06-29
- **Final completion:** 2021-06-29
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study never opened; closed on 06/29/2021 due to no enrllment
- **Last updated:** 2021-09-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03057990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03057990, "Pyrimethamine for Intermediate/High-risk Myelodysplastic Syndromes (MDS)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03057990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*